

LIFE – LIFECARE WILL PREPARE FOR UPLISTING TO THE MAIN LIST ON OSLO STOCK EXCHANGE

Bergen, Norway, February 21st, 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces today that the Board of Directors has decided to prepare for submitting application for listing of Lifecare's shares at the main list of Oslo Stock Exchange (OSE), transferring from the current listing on Euronext Growth.

- Stepping up to the major league at OSE is an important decision for Lifecare. We are comfortable with our organization's capability to adhere to the strict requirements and obligations connected with being listed at OSE, says CEO Joacim Holter at Lifecare.

Lifecare has been through a year with several milestone achievements when it comes to proof of concept of our cutting edge Sencell sensor. The company's CGM technology has proven its competitive properties in terms of accuracy, robustness, and longevity.

- We are now really on the brink of automated pilot production, and we see a new era for our sensor technology. We expect that a listing on the main list at Oslo Stock Exchange will further accelerate the overall growth of our company, attract, and secure a more flexible and even broader investor base that will support Lifecare in reaching our growth targets. We also expect that an uplisting will increase share liquidity and strengthen the profile of Lifecare, says Holter.

In accordance with the Board of Directors' decision, Lifecare management will prepare to submit the application for listing on OSE in the course of Q3 2024. The Board of Director's outlook for the Lifecare share is to be ready for trading on Oslo Børs' main list in October 2024, says Joacim Holter.

About us

Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body.



PRESS RELEASE
21 February 2024 08:00:00 CET

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs, asle.wingsternes@lifecare.no,
+47 41 61 42 52

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 19 no. 3. The information was submitted for publication at 2024-02-21 08:00 CET.